The ACC 2025 meeting is all wrapped up after matching the attendance and excitement of last year’s expo, with a clear trend toward better diagnostics and even better pharmaceuticals. Among dozens of highlights, here are Cardiac Wire’s seven biggest trends from ACC.25.
- Diverse Pharma – ACC.25 saw a deluge of pharmaceutical solutions across the spectrum of heart disease, from HCM all the way to LDL (detection and treatment just have to catch up).
- Cardiac CT’s Rise – It’s clear the cardiology industry is warming up to cardiac imaging as imaging OEMs released cheaper specialized cardiac CTs to meet growing demand as a result of encouraging reimbursement changes.
- Better Understanding TAVR – While TAVR has earned its reputation for safety and efficacy, several late breaking trials helped clarify ways to improve it and even complicate it.
- GLP-1s Are Dominating – From the banners flown to the booths presented, ACC.25 was brimming with GLP-1 research and marketing, speaking to the strong CV benefits we’re seeing from the drugs, even if the research isn’t clear on where these benefits come from.
- Reimbursement is Key – A common question asked at ACC.25 was “How do I get reimbursed?” That’s an important one to answer for clinicians, researchers, and businessmen alike whether it’s for imaging, drugs, or devices.
- AI Adoption Stays Strong – While there weren’t many AI-centered studies, many vendors incorporated AI into their products and marketing propositions, which suggests widespread adoption isn’t too far away.
- The Elephant in the Expo Center – While all of the new tech and drugs unveiled were undoubtedly exciting, they’re expensive, which could be a hurdle for the patients and providers who need them.
The Takeaway
From software and hardware innovations in the exhibit hall to strong pharma results in the late-breaking sessions, cardiac professionals have never had more technology and treatments at their disposal, but access for many breakthroughs still remains uncertain.
